Please use this identifier to cite or link to this item:
Title: Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies.
Austin Authors: Broadley, Simon A;Barnett, Michael H;Boggild, Mike;Brew, Bruce J;Butzkueven, Helmut;Heard, Robert;Hodgkinson, Suzanne;Kermode, Allan G;Lechner-Scott, Jeannette;Macdonell, Richard A L ;Marriott, Mark;Mason, Deborah F;Parratt, John;Reddel, Stephen W;Shaw, Cameron P;Slee, Mark;Spies, Judith;Taylor, Bruce V;Carroll, William M;Kilpatrick, Trevor J;King, John;McCombe, Pamela A;Pollard, John D;Willoughby, Ernest
Affiliation: Westmead Clinical School, University of Sydney, NSW, Australia
Hunter Medical Research Institute, The University of Newcastle, New Lambton, NSW, Australia
Department of Neurology, Austin Health, Heidelberg, Victoria, Australia
Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
Centre for Neuromuscular and Neurological Disorders, University of Western Australia, WA, Australia
University of Queensland Centre for Clinical Research, QLD, Australia
Institute of Immunology and Infectious Diseases, Murdoch University, WA, Australia
Department of Neurology, Gold Coast University Hospital, Southport, QLD, Australia
South Western Sydney Clinical School, University of New South Wales, NSW, Australia
Department of Neurology and St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, University of New South Wales, Darlinghurst, NSW, Australia
Central Clinical School, University of Sydney, NSW, Australia
School of Medicine, Deakin University, Victoria, Australia
Department of Neurology, The Townsville Hospital, Douglas, QLD, Australia
Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia
Centre for Neuroscience and Flinders Medical Centre, Flinders University, SA, Australia
Menzies Research Institute, University of Tasmania, TAS, Australia
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia
School of Medicine, Griffith University, Gold Coast Campus, QLD 4222, Australia
Department of Neurology, Christchurch Hospital, Christchurch, New Zealand.
Department of Neurology, Auckland City Hospital, Auckland, New Zealand.
Issue Date: 30-Jun-2014
Publication information: Journal of Clinical Neuroscience 2014; 21(11): 1835-46
Abstract: Multiple sclerosis (MS) is a potentially life-changing immune mediated disease of the central nervous system. Until recently, treatment has been largely confined to acute treatment of relapses, symptomatic therapies and rehabilitation. Through persistent efforts of dedicated physicians and scientists around the globe for 160 years, a number of therapies that have an impact on the long term outcome of the disease have emerged over the past 20 years. In this three part series we review the practicalities, benefits and potential hazards of each of the currently available and emerging treatment options for MS. We pay particular attention to ways of abrogating the risks of these therapies and provide advice on the most appropriate indications for using individual therapies. In Part 1 we review the history of the development of MS therapies and its connection with the underlying immunobiology of the disease. The established therapies for MS are reviewed in detail and their current availability and indications in Australia and New Zealand are summarised. We examine the evidence to support their use in the treatment of MS.
Gov't Doc #: 24993135
DOI: 10.1016/j.jocn.2014.01.016
Type: Journal Article
Subjects: Evidence-based medicine
Multiple sclerosis
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 5, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.